Europe Plasma Fractionation Market

Market Introduction

The Europe plasma fractionation market includes the consolidated markets for Germany, France, UK, Spain, Italy, and rest of Europe. Europe occupies a significant position in the global plasma fractionation market and is estimated to register a robust growth rate over the forecast period. The market growth in the region is expected due to aging population, increasing use of immunoglobulins to treat various chronic diseases, increasing prevalence of immune and bleeding disorders and surge in plasma therapies for disease management are all expected to drive market growth for Europe region during the forecast period.

In European countries, the medical practice of various chronic diseases such as neurological disorders, hematological disorders, and respiratory diseases has changed. Due to the diversification of the medical staff and the decision to focus on treating the critically ill, rising COVID-19 has impacted illness detection and treatment. Due to the current pandemic, many research organizations are focusing more on COVID-19 studies and are working hard to understand the virus better. Some of the federal agencies in the region have taken the initiative to adopt plasma therapy to treat COVID-19 patients. For instance, the National Agency for Medicines and Health Products Safety of France (ANSM) announced that immune plasma therapy would be used in treating critically ill patients. Also, the European Commission recommended the emergency use of convalescent plasma therapy to treat critical patients. Thus, the use of plasma therapies in the management of COVID-19 has positively impacted the market to some extent. However, due to COVID-19, the overall medical practice of neurological disorders, hematological disorders, and idiosyncratic disorders has changed, and the majority of pharmaceutical and biopharmaceutical companies are emphasizing on developing novel treatment therapies for COVID-19, which is negatively impacting the market growth.                  

Market Overview and Dynamics

The plasma fractionation market in Europe is expected to grow from US$ 6,824.67 million in 2021 to US$ 10,402.95 million by 2028; it is estimated to grow at a CAGR of 6.2% from 2021 to 2028. Increasing geriatric population, increasing use of immunoglobulins in various therapeutic areas such as neurology, hematology, rare genetic disorders and autoimmune disorders along with growing demand for plasma derived therapies for management of diseases are all expected to boost plasma fractionation market in rest of Europe. Furthermore, various companies in Europe are investing more on research and development activities to develop and launch novel approaches in plasma therapies for management of diseases.     

Key Market Segments

Europe plasma fractionation market is segmented into product, application, end user, and country. The Europe plasma fractionation market, based on product, has been segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and others. The immunoglobulin segment is likely to hold the largest share of the market in 2021. The Europe plasma fractionation market, based on application is segmented into neurology, immunology, hematology, critical care, pulmonology, and others. In 2021, the Neurology segment is likely to hold the largest share of the market. The Europe plasma fractionation market, based on end user is segmented into hospitals and clinics, clinical research laboratories, academic institutes. In 2021, the hospitals and clinics segment is likely to hold the largest share of the market. Based on country, the Europe plasma fractionation market is segmented into France, Germany, Italy, Spain, the UK, and rest of Europe. Rest of Europe held the largest market share in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the plasma fractionation market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bharat Serums and Vaccines Limited (BSV); Bio Products Laboratory Ltd.; Biotest AG; CSL Limited; Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Sanquin; and SK Plasma.          

Reasons to buy report

• To understand the Europe plasma fractionation market landscape and identify market segments that are most likely to guarantee a strong return.
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe plasma fractionation market.
• Efficiently plan M&A and partnership deals in Europe plasma fractionation market by identifying market segments with the most promising probable sales.
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe plasma fractionation market.
• Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

Europe Plasma Fractionation Market Segmentation

Europe Plasma Fractionation Market - By Product

• Immunoglobulin
  • Intravenous Immunoglobulin (IVIG)
  • Subcutaneous Immunoglobulin (SCIG)
• Albumin
• Coagulation Factor Concentrates
• Protease Inhibitors
• Other

Europe Plasma Fractionation Market - By Application

• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Others

Europe Plasma Fractionation Market - By End User

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

Europe Plasma Fractionation Market - By Country

• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe

Europe Plasma Fractionation Market - Company Profiles

• Bharat Serums and Vaccines Limited (BSV)
• Bio Products Laboratory Ltd.
• Biotest AG.
• CSL Limited
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma AG
• Sanquin
• SK Plasma

Europe Plasma Fractionation Market Strategic Insights

Europe Plasma FractionationMarket Report Highlights

Europe Plasma Fractionation Market Country and Regional Insights